Skip to Content

Ifosfamide / mesna Disease Interactions

There are 3 disease interactions with ifosfamide / mesna:

Major

Antineoplastics (Includes Ifosfamide/mesna) ↔ Infections

Severe Potential Hazard, High plausibility

Applies to: Infection - Bacterial/Fungal/Protozoal/Viral

Because of their cytotoxic effects on rapidly proliferating tissues, antineoplastic agents frequently can, to varying extent, induce myelosuppression. The use of these drugs may be contraindicated in patients with known infectious diseases. All patients should be instructed to immediately report any signs or symptoms suggesting infection such as fever, sore throat, or local infection during antineoplastic therapy. Close clinical monitoring of hematopoietic function is recommended.

References

  1. "Product Information. Novantrone (mitoxantrone)." Immunex Corporation, Seattle, WA.
  2. "Product Information. Gemzar (gemcitabine)." Lilly, Eli and Company, Indianapolis, IN.
  3. "Product Information. Fludara (fludarabine)." Berlex, Richmond, CA.
  4. "Product Information. Taxol (paclitaxel)." Bristol-Myers Squibb, Princeton, NJ.
  5. "Product Information. Leukeran Tablets (chlorambucil)." Glaxo Welcome, Research Triangle Pk, NC.
  6. "Product Information. Doxil (doxorubicin liposomal)." Sequis Pharmaceuticals Inc, Menlo Park, CA.
  7. Frame JN, Dahut WL, Crowley S "Fludarabine and acute tumor lysis in chronic lymphocytic leukemia." N Engl J Med 327 (1992): 1396-7
  8. "Product Information. Leustatin (cladribine)." Ortho Biotech Inc, Raritan, NJ.
  9. "Product Information. Matulane (procarbazine)." Roche Laboratories, Nutley, NJ.
  10. Sanders C, Perez EA, Lawrence HJ "Opportunistic infections in patients with chronic lymphocytic leukemia following treatment with fludarabine." Am J Hematol 39 (1992): 314-5
  11. "Product Information. Mutamycin (mitomycin)." Bristol-Myers Squibb, Princeton, NJ.
  12. "Product Information. Tabloid (thioguanine)." Glaxo Wellcome, Research Triangle Park, NC.
  13. "Product Information. Taxotere (docetaxel)." Rhone-Poulenc Rorer, Collegeville, PA.
  14. "Product Information. Idamycin (idarubicin)." Pharmacia and Upjohn, Kalamazoo, MI.
  15. "Product Information. Platinol (cisplatin)." Bristol-Myers Squibb, Princeton, NJ.
  16. "Product Information. Purinethol (mercaptopurine)." Glaxo Wellcome, Research Triangle Pk, NC.
  17. "Product Information. Methotrexate (methotrexate)." Lederle Laboratories, Wayne, NJ.
  18. "Product Information. Xeloda (capecitabine)." Roche Laboratories, Nutley, NJ.
  19. "Product Information. Nipent (pentostatin)." Parke-Davis, Morris Plains, NJ.
  20. "Product Information. Adriamycin PFS (doxorubicin)." Pharmacia and Upjohn, Kalamazoo, MI.
  21. "Product Information. DTIC-Dome (dacarbazine)." Bayer, West Haven, CT.
  22. "Product Information. Alkeran Tablets (melphalan)." Glaxo Wellcome, Research Triangle Pk, NC.
  23. Schilling PJ, Vadhan-Raj S "Concurrent cytomegalovirus and pneumocystis pneumonia after fludarabine therapy for chronic lymphocytic leukemia." N Engl J Med 323 (1990): 833-4
  24. "Product Information. Thiotepa (thiotepa)." Lederle Laboratories, Wayne, NJ.
  25. Bastion Y, Coiffier B, Tigaud JD, Espinouse D, Bryon PA "Pneumocystis pneumonia in a patient treated with fludarabine for chronic lymphocytic leukemia." Eur J Cancer 27 (1991): 671
  26. "Product Information. Ifex (ifosfamide)." Bristol-Myers Squibb, Princeton, NJ.
  27. "Product Information. Hycamtin (topotecan)." SmithKline Beecham, Philadelphia, PA.
  28. "Product Information. Cytosar-U (cytarabine)." Pharmacia and Upjohn, Kalamazoo, MI.
  29. Girmenia C, Mauro FR, Rahimi S "Late listeriosis after fludarabine plus prednisone treatment." Br J Haematol 87 (1994): 407-8
  30. "Product Information. Vepesid (etoposide)." Bristol-Myers Squibb, Princeton, NJ.
  31. "Product Information. Uracil Mustard (uracil mustard)." Roberts Pharmaceutical Corporation, Eatontown, NJ.
View all 31 references
Major

Mdvs (Includes Ifosfamide/mesna) ↔ Prematurity

Severe Potential Hazard, Moderate plausibility

Applies to: Prematurity/Underweight in Infancy

Parenteral medications formulated in multidose vials often contain benzyl alcohol as a preservative. Their use is considered by drug manufacturers to be contraindicated in neonates, particularly premature infants and infants of low birth weight. When used in bacteriostatic saline intravascular flush and endotracheal tube lavage solutions, benzyl alcohol has been associated with fatalities and severe respiratory and metabolic complications in low-birth-weight premature infants. Thus, single-dose formulations should always be used in infants whenever possible. However, many experts feel that, in the absence of benzyl alcohol-free equivalents, the amount of the preservative present in these formulations should not necessarily preclude their use if they are clearly indicated. The American Academy of Pediatrics considers benzyl alcohol in low doses (such as when used as a preservative in some medications) to be safe for newborns. However, the administration of high dosages of these medications must take into account the total amount of benzyl alcohol administered. The level at which toxicity may occur is unknown.

References

  1. ""Inactive" ingredients in pharmaceutical products: update (subject review). American Academy of Pediatrics Committee on Drugs. Available from: URL: http://www.aap.org/policy/re9706.html." Pediatrics 99 (1997): 268-78
  2. "Product Information. Tracrium (atracurium)." Glaxo Wellcome, Research Triangle Park, NC.
  3. "Product Information. Fragmin (dalteparin)." Pharmacia and Upjohn, Kalamazoo, MI.
  4. "Product Information. Nuromax (doxacurium)." Glaxo Wellcome, Research Triangle Park, NC.
  5. "Product Information. Mivacron (mivacurium)." Glaxo Wellcome, Research Triangle Park, NC.
  6. "Product Information. Mesnex (mesna)." Bristol-Myers Squibb, Princeton, NJ.
View all 6 references
Major

Mesna (Includes Ifosfamide/mesna) ↔ Autoimmune Disorders

Severe Potential Hazard, Moderate plausibility

Applies to: Autoimmune Disorder

Mesna is a thiol (SH) compound. Hypersensitivity reactions including anaphylaxis have occurred in patients with autoimmune disorders, the majority of whom received high dosages of mesna orally. Therapy with mesna should be administered cautiously in patients with autoimmune disorders.

References

  1. Reinhold-Keller E, Mohr J, Christophers E, Nordmann K, Gross WL "Mesna side effects which imitate vasculitis." Clin Investig 70 (1992): 698-704
  2. Seidel A, Andrassy K, Ritz E, Kasser U, Lemmel EM "Allergic reactions to mesna." Lancet 338 (1991): 381
  3. "Product Information. Mesnex (mesna)." Bristol-Myers Squibb, Princeton, NJ.
  4. Lang E, Goos M "Hypersensitivity to mesna." Lancet 2 (1985): 329
  5. Zonzits E, Aberer W, Tappeiner G "Drug eruptions from mesna. After cyclophosphamide treatment of patients with systemic lupus erythematosus and dermatomyositis." Arch Dermatol 128 (1992): 80-2
View all 5 references

ifosfamide / mesna drug Interactions

There are 765 drug interactions with ifosfamide / mesna

ifosfamide / mesna alcohol/food Interactions

There is 1 alcohol/food interaction with ifosfamide / mesna

Drug Interaction Classification

The classifications below are a general guideline only. It is difficult to determine the relevance of a particular drug interaction to any individual given the large number of variables.
Major Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit.
Moderate Moderately clinically significant. Usually avoid combinations; use it only under special circumstances.
Minor Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan.
Unknown No information available.

Do not stop taking any medications without consulting your healthcare provider.

Disclaimer: Every effort has been made to ensure that the information provided by Multum is accurate, up-to-date and complete, but no guarantee is made to that effect. In addition, the drug information contained herein may be time sensitive and should not be utilized as a reference resource beyond the date hereof. This material does not endorse drugs, diagnose patients, or recommend therapy. Multum's information is a reference resource designed as supplement to, and not a substitute for, the expertise, skill, knowledge, and judgement of healthcare practitioners in patient care. The absence of a warning for a given drug or combination thereof in no way should be construed to indicate that the drug or combination is safe, effective, or appropriate for any given patient. Multum Information Services, Inc. does not assume any responsibility for any aspect of healthcare administered with the aid of information Multum provides. Copyright 2000-2018 Multum Information Services, Inc. The information contained herein is not intended to cover all possible uses, directions, precautions, warnings, drug interactions, allergic reactions, or adverse effects. If you have questions about the drugs you are taking, check with your doctor, nurse, or pharmacist.

Hide